Showing 1,601 - 1,620 results of 102,596 for search '(( 50 ((nn decrease) OR (mean decrease)) ) OR ( 5 ((fold decrease) OR (a decrease)) ))', query time: 1.27s Refine Results
  1. 1601
  2. 1602

    Fig 6 - by Dennis Ochola (11626912)

    Published 2022
    Subjects:
  3. 1603
  4. 1604
  5. 1605
  6. 1606
  7. 1607
  8. 1608
  9. 1609
  10. 1610
  11. 1611

    <i>B-MOBILE</i> - A Smartphone-Based Intervention to Reduce Sedentary Time in Overweight/Obese Individuals: A Within-Subjects Experimental Trial by Dale S. Bond (588506)

    Published 2014
    “…Average % SED at baseline (72.2%) decreased by 5.9%, 5.6%, and 3.3% [i.e. by mean (95% CI) −47.2(−66.3, −28.2), −44.5(−65.2, −23.8), and −26.2(−40.7, −11.6) min/d] in the 3-, 6-, and 12-min conditions, respectively. …”
  12. 1612
  13. 1613
  14. 1614
  15. 1615

    p35 siRNA knockdown decreased Cdk5 activity, diminished WT1 expression and viable cell numbers, but did not affect a cell apoptosis marker as detected by WB. by Ya-Li Zheng (454837)

    Published 2016
    “…A&B. Western blots show that p35 siRNA-transfected podocytes successfully decrease p35 expression (upper panel, lane 2) compared to the control siRNA cells (p<0.05), but did not affect cyclin I expression (3<sup>rd</sup> panel). …”
  16. 1616
  17. 1617

    Activation of GluR5 increased neuronal excitability in interneruons but decreased excitability in pyramidal neurons. by Long-Jun Wu (47043)

    Published 2013
    “…Resting membrane potential for this neuron was −66.6 mV and the holding current was 66.9 pA. (H) Pooled data showed that ATPA (3 µM) increased firing rate of interneurons (n = 6) while decreased that of pyramidal neurons (n = 5). …”
  18. 1618
  19. 1619
  20. 1620

    Table_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

    Published 2022
    “…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”